Announcement PDF Invion strengthens Scientific Advisory Board - appoints cancer experts Highlights • • • Cancer therapy developer Invion Limited strengthens Scientific Advisory Board, appointing experts in skin, lung and prostate cancer New appointees are Dr Lynda Spelman (skin cancer), Assoc. Prof Louis Irving (lung cancer), and Assoc. Prof Nathan Lawrentschuk (urological cancer including prostate cancer) Invion says the appointments will advance clinical development and help ensure that the Invion drugs and devices are optimised for each cancer type Melbourne, Australia, 16 January 2019: Cancer therapy developer Invion Ltd (ASX: IVX) (“Invion” or “the Company”) has strengthened its scientific expertise, appointing three new members to the Company’s Scientific Advisory Board (SAB), which is expected to advance plans for clinical trials. The three new appointees – Dr Lynda Spelman, Associate Professor Louis Irving and Associate Professor Nathan Lawrentschuk – are consultants in skin cancer, lung cancer and urological cancer respectively. Invion is developing photodynamic therapies – based on the licensed Photosoft technology for a range of cancers, including skin, ovarian, prostate and lung cancer. Photodynamic therapy (PDT) uses non-toxic photosensitisers (molecules that produce a chemical change in another molecule in a photochemical process) and visible light in combination with oxygen to produce a reaction that kills cancer cells, shuts down tumours and stimulates the immune system. Invion Chief Executive Officer Dr Greg Collier said the three new SAB members are amongst Australia’s foremost experts in their fields. “They bring a wealth of academic and clinical experience and have previously interacted positively with industry over a number of years,” Dr Collier said. “The appointments will advance our clinical planning and ensure that Invion’s drug development is optimised for each different cancer type.” Skin cancer consultant Dr Lynda Spelman is a specialist dermatologist with 26 years experience in dermatology and a special interest in clinical research trials. She is the founder and a director of the Queensland Institute of Dermatology and a principal investigator for Veracity Clinical Research. Dr Spelman has conducted studies on a wide range of dermatological conditions, including and superficial and nodular basal cell carcinoma. The appointment of Dr Spelman is timely as Invion plans to have a gel formulation of its improved photosensitiser product IVX-P02 for the treatment of skin cancer ready in 2019 for testing in human clinical studies. Invion Limited ABN 76 094 730 417 722 High Street, East Kew, VIC 3102 Australia P: +61 3 9081 6005 W: www.inviongroup.com Lung cancer consultant Assoc. Prof Louis Irving is a lung cancer and respiratory physician at the Peter MacCallum Cancer Centre, and director of clinical training at Royal Melbourne Hospital. He also holds principal fellowships at the University of Melbourne, in the Faculty of Medicine and the Department of Physiology. Assoc. Prof Irving has clinical, teaching and research interests in lung cancer, advanced bronchoscopy and COPD (chronic obstructive pulmonary disease) and has published more than 200 scientific papers. Urological cancer consultant Assoc. Prof Nathan Lawrentschuk is a urologic oncologist and director of the EJ Whitten Prostate Cancer Research Centre at Epworth Healthcare. He is also a urological cancer surgeon and oncologist at the Peter MacCallum Cancer Centre, and holds appointments at the University of Melbourne’s Department of Surgery, Olivia NewtonJohn Cancer Centre at the Austin Hospital, Melbourne. The appointment of Assoc. Prof Irving and Assoc. Prof Lawrentschuk come ahead of the company’s operational expansion into intravenous treatment uses for its PDT treatment in lung and prostate cancer. ENDS About Invion Invion is a clinical-stage life-sciences company that holds the Australia and New Zealand license to the PhotosoftTM technology for the treatment of all cancers. Research and clinical trials are funded by the technology licensor, The Cho Group, which will provide non-dilutive funding to the Company. Invion is listed on ASX (ASX: IVX). About Photodynamic Therapy (PDT) Invion is developing PhotosoftTM technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. In contrast to surgery, or radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heatshock proteins, and invasion and infiltration of a tumour by leukocytes. ____________________________________________ Investor enquiries Managing Director & CEO, Dr Greg Collier T: +61 3 9081 6005 E: investor@inviongroup.com Invion Limited ABN 76 094 730 417 722 High Street, East Kew, VIC 3102 Australia P: +61 3 9081 6005 W: www.inviongroup.com